RECRUITINGOBSERVATIONAL
Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
About This Trial
This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development of infants and children with Cystic Fibrosis (CF).
Who May Be Eligible (Plain English)
Who May Qualify:
- Infants with a confirmed diagnosis of CF by NBS
- Age \<=18 years
- Written willing to sign a consent form by patient and/or parent
Who Should NOT Join This Trial:
- Need for respiratory support for more than three days
- Severe malformations or known diseases other than CF
- Maternal drug abuse
- Known severe maternal disease
- Severe Problems of communication
- Pacemaker, continuous glucose monitor
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Infants with a confirmed diagnosis of CF by NBS
* Age \<=18 years
* Written informed consent by patient and/or parent
Exclusion Criteria:
* Need for respiratory support for more than three days
* Severe malformations or known diseases other than CF
* Maternal drug abuse
* Known severe maternal disease
* Severe Problems of communication
* Pacemaker, continuous glucose monitor
Treatments Being Tested
OTHER
no intervention
Locations (1)
University Children's Hospital Bern
Bern, Switzerland